Envoy Medical first patients reach 12-month trial endpoint for implant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
April 1, 2026 8:02 AM EDTCompany Remains on Schedule for PMA Submission to FDA
White Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical, Inc.(NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's progress.
The first three pivotal trial patients implanted at the start of 2025 are now the... More
